IRLAB to present clinical and preclinical data at the AD/PD™ 2025: 19th International Conference on Alzheimer’s & Parkinson’s Diseases
Gothenburg, Sweden, April 1, 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that it will showcase three abstracts at the AD/PDTM 2025: 19th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, taking place in Vienna, Austria, April 1-5, 2025.
Read More >Watch IRLAB’s
Capital Markets Day 2023!
ISP – The proprietary technology platform
IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.
IRLAB’s clinical phase II candidates
Mesdopetam (IRL790)
In development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease.
Pirepemat (IRL752)
In development to treat impaired balance (postural dysfunction) leading to falls in Parkinson’s disease.
Presentation at Redeye’s Theme Event Neurology
Presentation by Kristina Torfgård, CEO, at “Theme Event Neurology”, an event hosted by Redeye, held on October 23, 2024.
Read More >